Anti-trust authorities in the U.K. this month declined to open a probe into Zoll Medical‘s acquisition of Philips‘ (NYSE:PHG) InnerCool business and its catheter-based endovascular and surface temperature management technologies.
Zoll said last Nov. 17 that it agreed to buy the InnerCool assets for an undisclosed amount. The U.K.’s Competition & Market’s Authority said it received a complaint about the merger Dec. 8 and undertook an "own-initiative assessment" of the deal Dec. 12.
"On the basis of the information available to it from the parties and 3rd parties, the CMA has decided that the merger does not qualify for investigation,"the CMA said today.
The InnerCool assets, all cleared by the FDA, include InnerCool’s RTx endovascular system, the Accutrol catheter and the CoolRepeat and STx surface cooling systems.
InnerCool is slated to be integrated into Zoll’s temperature management business in San Jose, Calif.
